Hairy cell leukemia – etiopathogenesis, diagnosis and modern therapeutic approach
Biochemia medica · 2024
DOI: 10.11613/bm.2024.020502 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemia medica, 2024. Verfasst von Katarzyna Maćkowiak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Diagnostic, Dr Jan Biziel University Hospital No. 2, Bydgoszcz, Poland. Hauptthemen laut MEDLINE: Leukemia, Hairy Cell. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Graphical abstract Highlights • A chronic lymphoproliferative disease with characteristic mature clonal B lymphocytes with hairy protrusions • Associated with impaired activity of the B-rapidly accelerated fibrosarcoma (BRAF) protein • Differential diagnosis of hairy cell leukemia, hairy cell leukemia variant and splenic marginal zone lymphoma allows for the selection of effective pharmacological therapy and for risk stratification • Therapeutic approach includes purine analogues, BRAF kinase inhibitors, and anticancer immunotherapy Hairy cell leukemia (HCL) represents 2% of all leukemia cases, with men aged above 55 years being the most affected. The most common symptoms of this type of leukemia include splenomegaly, monocytopenia, and neutropenia. In the basic blood count examination, leukopenia with monocytopenia and granulocytopenia, as well as aplastic anemia and/or thrombocytopenia occur. The mutation of β-rapidly accelerated fibrosarcoma (BRAF) proto-oncogene, which can be found in nearly 100% of patients, is an important feature of HCL. Immunophenotypic analysis of the HCL cells reveals high expression of B-lineage antigens, including CD19, CD20, and CD22. Additionally, CD11c, CD25, CD103, and CD123 belong to specific markers of HCL. Lactate dehydrogenase activity and β-2-microglobulin concentration are also important in the patient’s assessment. The differential diagnosis between HCL, hairy cell leukemia variant (HCL-V) and splenic marginal zone lymphoma (SMZL) is of first importance. Currently, the main treatment for HCL involves the use of purine analogues, excluding pregnant women, individuals with severe infections, and those with relapsing HCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Diagnostic, Dr Jan Biziel University Hospital No. 2, Bydgoszcz, Poland.
- Department of Medical Biology and Biochemistry, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland.
- Department of Pathobiochemistry and Clinical Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland.
Zitieren
APA
Maćkowiak, K., Jankowiak, M., Szewczyk-Golec, K., & Hołyńska-Iwan, I. (2024). Hairy cell leukemia – etiopathogenesis, diagnosis and modern therapeutic approach. Biochemia medica. https://doi.org/10.11613/bm.2024.020502
Vancouver
Maćkowiak K, Jankowiak M, Szewczyk-Golec K, Hołyńska-Iwan I. Hairy cell leukemia – etiopathogenesis, diagnosis and modern therapeutic approach. Biochemia medica. 2024. doi:10.11613/bm.2024.020502
BibTeX
@article{Makowiak2024,
author = {Maćkowiak, Katarzyna and Jankowiak, Magdalena and Szewczyk-Golec, Karolina and Hołyńska-Iwan, Iga},
title = {Hairy cell leukemia – etiopathogenesis, diagnosis and modern therapeutic approach},
journal = {Biochemia medica},
year = {2024},
doi = {10.11613/bm.2024.020502}
}
EUVIMED